Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: B-cell chronic lymphocytic leukemia is a clinically heterogeneous disease; some patients rapidly progress and die within a few years of diagnosis, whereas others have a long life expectancy with minimal or no treatment. Telomere length and telomerase levels have been proposed as prognostic factors; however, very few cases have been characterized for both parameters and no study has analyzed the prognostic value of the telomere/telomerase profile. DESIGN AND METHODS: One hundred and seventy-three cases of chronic lymphocytic leukemia were characterized for telomere lengths and telomerase levels by real-time polymerase chain reaction. Data were correlated with established prognostic markers, IGVH mutational status and chromosomal aberrations, and clinical outcome. RESULTS: Telomere lengths were inversely correlated with telomerase levels (r(s) = -0.213; P = 0.012), and most of the cases of chronic lymphocytic leukemia with high levels (above median) of telomerase had short (below median) telomeres (P = 0.0001). Telomerase levels were higher and telomeres were shorter in unmutated IGVH cases than in mutated IGVH ones (P<0.0001). Chronic lymphocytic leukemias with 11q, 17p deletion or 12 trisomy had significantly higher levels of telomerase and shorter telomeres than those with no chromosomal aberration or the sole 13q deletion (P < 0.001). Telomere length/telomerase level profiles identified subgroups of patients with different clinical outcomes (P < 0.0001), even within the subsets of chronic lymphocytic leukemia defined by IGVH mutational status or chromosomal aberrations. Short telomere/high telomerase profile was independently associated with more rapid disease progression. CONCLUSIONS: Comprehensive analyses of telomeres, telomerase, chromosomal aberrations, and IGVH mutational status delineate groups of chronic lymphocytic leukemias with distinct biological characteristics and clinical outcomes. The telomere/telomerase profile may be particularly useful in refining the prognosis of chronic lymphocytic leukemia patients with mutated IGVH and no high-risk chromosomal aberrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,318
Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia
Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G., & Stevenson, F. K. (1999) · Blood · doi:10.1182/blood.v94.6.1848 · Cited by 2,783
Telomerase Catalytic Subunit Homologs from Fission Yeast and Human
Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., & Cech, T. R. (1997) · Science · doi:10.1126/science.277.5328.955 · Cited by 2,256
Morin, G. B. (1989) · Cell · doi:10.1016/0092-8674(89)90035-4 · Cited by 1,495 · cited 1×
“High hTERT and short telomeres as prognostic markers of poor clinical outcome Disease progression, estimated as TTFT, was more rapid in B-CLL with high hTERT levels than in those with low hTERT levels [median (95% CI) 31 (19;50) versus 104 (66;-) months; P<0.”
BackgroundTelomeres and telomerase in cancer
Artandi, S. E., & DePinho, R. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp268 · Cited by 823 · cited 5×
“hTERT levels were significantly higher in B-CLL with 11q- or 17p- and lower in B-CLL with 13q- [median (IQR) 94 (40-250), 235 (107-618), 159 (87-359), and 56 (20-166) in normal, 11q-/ 17p-, +12, and 13q- B-CLL, respectively; P=0.”
BackgroundResultInfluentialTelomere Length Abnormalities Occur Early in the Initiation of Epithelial Carcinogenesis
Meeker, A. K., Hicks, J. L., Iacobuzio-Donahue, C. A., Montgomery, E. A., Westra, W. H., Chan, T. Y., Ronnett, B. M., & De Marzo, A. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0984-03 · Cited by 306
Lin, T. T., Letsolo, B. T., Jones, R. E., Rowson, J., Pratt, G., Hewamana, S., Fegan, C., Pepper, C., & Baird, D. M. (2010) · Blood · doi:10.1182/blood-2010-02-272104 · Cited by 178
Hou, M., Xu, D., Björkholm, M., & Gruber, A. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.3.519 · Cited by 175
hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway
Massard, C., Zermati, Y., Pauleau, A.-L., Larochette, N., Métivier, D., Sabatier, L., Kroemer, G., & Soria, J.-C. (2006) · Oncogene · doi:10.1038/sj.onc.1209487 · Cited by 144
Rampazzo, E., Bertorelle, R., Serra, L., Terrin, L., Candiotto, C., Pucciarelli, S., Bianco, P. D., Nitti, D., & De Rossi, A. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605644 · Cited by 125 · cited 5×
“hTERT levels were significantly higher in B-CLL with 11q- or 17p- and lower in B-CLL with 13q- [median (IQR) 94 (40-250), 235 (107-618), 159 (87-359), and 56 (20-166) in normal, 11q-/ 17p-, +12, and 13q- B-CLL, respectively; P=0.”
BackgroundResultInfluentialSelf-citation
Cited by
Ojha, J., Codd, V., Nelson, C. P., Samani, N. J., Smirnov, I. V., Madsen, N. R., Hansen, H. M., de Smith, A. J., Bracci, P. M., Wiencke, J. K., et al. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-1329 · Cited by 71
Cell-extrinsic consequences of epithelial stress: activation of protumorigenic tissue phenotypes
Fordyce, C. A., Patten, K. T., Fessenden, T. B., DeFilippis, R., Hwang, E. S., Zhao, J., & Tlsty, T. D. (2012) · Breast Cancer Research · doi:10.1186/bcr3368 · Cited by 50
Immune senescence and cancer in elderly patients: Results from an exploratory study
Falci, C., Gianesin, K., Sergi, G., Giunco, S., De Ronch, I., Valpione, S., Soldà, C., Fiduccia, P., Lonardi, S., Zanchetta, M., et al. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.09.011 · Cited by 46
Self-citation
Metadata
- Authors
- Rampazzo, E., Bonaldi, L., Trentin, L., Visco, C., Keppel, S., Giunco, S., Frezzato, F., Facco, M., Novella, E., Giaretta, I., Del Bianco, P., Semenzato, G., & De Rossi, A.
- Venue
- Haematologica
- Published
- 2011-09-20
- Volume
- 97
- Issue
- 1
- Pages
- 56-63
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2047848612
- Cited by
- 66
- References
- 10
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. https://app.cochat.ai/papers/10.3324/haematol.2011.049874
- The paper
- Rampazzo, E., Bonaldi, L., Trentin, L., Visco, C., Keppel, S., Giunco, S., Frezzato, F., Facco, M., Novella, E., Giaretta, I., Del Bianco, P., Semenzato, G., & De Rossi, A. (2012). Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica. https://doi.org/10.3324/haematol.2011.049874
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.